News
GlobalData on MSN10h
Novartis’ Cosentyx shows no benefit in Phase III GCA trialNovartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or ...
Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback